Category:

Gene Therapy

Description:

The present invention slectivly target elongation factor 2 (EF2) in cancer cells by generating an adenovirus with two novel features.  The virus can only replicate in cancer cells, and it expresses an inducible shRNA against EF2.  Preliminary studies in vitro show that shRNA against EF2 are promising.  The resulting invention would likely result in a novel approach to targeting specific cancers in the human body.

Potential Applications:

• Target and destroy cancer cells without affecting normal cells
• Novel Therapeutic
• Potential Platform Technology

Inventor(s):

Dr. Christina Voelkel-Johnson

Patent Status:

Availability:

Available for:
exclusive
non-exclusive
licensing.

Technology Status:

Licensing Contact:

Ryan N. Fiorini, MBA, Ph.D.
MUSC Foundation for Research Development
PO Box 250828
Charleston, SC 29425
843.876.1906
fiorinir@musc.edu